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Introduction
Asthma is a chronic inflammatory disease of the 
airways. There is increasing evidence that phenotyping 
asthma according to airway inflammation allows the 
identification of subgroups of patients that are more 
likely to respond to targeted therapy. The importance of 
these inflammatory phenotypes is that the underlying 
molecular mechanisms are different. While the 
eosinophilic phenotype is likely to reflect ongoing 
adaptive immunity in response to allergen with Th2 
cytokine IL-4, IL-5 and IL-13 playing a key role, the 
neutrophilic is thought to reflect innate immune system 
activation in response to pollutants or infectious agents 
[1, 2]. Those phenotypes actually require different 
therapeutic treatments. Importantly, studies have 
confirmed that eosinophilic airway inflammation most 
reliably predicts the response to anti-inflammatory 
treatment such as inhaled corticosteroid [3, 4] and anti-
IL5 [5, 6]. Studies have demonstrated the usefulness 
of induced sputum to guide asthma treatment [7, 
8]. These studies showed that normalizing airway 
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Abstract
Inflammation associated oxidative stress leads to peroxidation of polyunsaturated fatty acids thereby 
generating volatile organic compounds (VOCs). The integrative analysis of the total amount of 
VOCs released by eosinophils and neutrophils in vitro enables the search for those compounds that 
discriminates between various inflammatory conditions.
The approach comprises isolating eosinophils and neutrophils from 30 ml of blood of healthy 
non-smoking volunteers by gradient centrifugation, using lymphoprep. Eosinophils are separated 
from neutrophils by immunomagnetic cell separation using anti-CD16. Cells are activated with 
phorbol 12-myristate 13-acetate and VOCs from the headspace are collected at time 0′, 30′, 60′ and 
90′ by introduction of ultra-pure nitrogen in the closed flasks at a flow rate of 200 ml min−1 during 
10 min. The gases are trapped onto a sorption tube and analyzed by gas chromatography—time-of-
flight—mass spectometry (GC-TOF-MS) in order to identify VOCs released in the headspace by 
activated neutrophils and eosinophils.
Eosinophils and neutrophils were isolated from 26 healthy non-smoking volunteers. The average 
absolute number of eosinophils and neutrophils upon isolation was 3.5  ×  106 and 19.4  ×  106, 
respectively. The volatome in headspace consisted of 2116 compounds and those compounds 
present in at least 8% of the samples (1123 compounds) were used for further discriminant analysis. 
Discriminant analysis showed that two VOCs were able to distinguish between eosinophilic and 
neutrophilic cultures in the unactivated state with 100% correct classification of the entire data set 
and upon cross validation while five VOCs were able to discriminate between activated eosinophils 
and neutrophils with 96% correct classification in the original set and upon cross-validation.
Analysis of VOCs seems to be a very promising approach in identifying eosinophilic and 
neutrophilic inflammation but it needs further development and in vivo confirmation.
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eosinophilic inflammation allowed better control 
of asthma with reduced exacerbations and hospital 
admissions. There is, however, no evidence that inhaled 
corticosteroids may improve asthma control in the 
absence of uncontrolled eosinophilic inflammation as 
encountered in pauci-granulocytic asthma [9] and data 
suggest that severe neutrophilic asthma could be best 
targeted by using clarithromycin [10, 11].
The technique of induced sputum that allows 
collection of airway cells is considered as the gold stand-
ard to identify asthma inflammatory phenotypes [12]. 
It is, however, technically demanding and time consum-
ing. Alternative biomarkers such as FENO have already 
been identified [13, 14] but thresholds predicting 
eosinophilic inflammation varies according to inhaled 
corticosteroids (ICS) and smoking habit. Inflamma-
tion associated oxidative stress leads to peroxidation of 
polyunsaturated fatty acids thereby generating volatile 
organic compounds (VOCs). VOC profiles have been 
shown to be able to discriminate between various pul-
monary diseases conditions [15–17]. Analysis of VOCs 
derived from influxed eosinophils and neutrophils may 
offer the possibility of noninvasive monitoring of the 
associated type of inflammation. Therefore we meas-
ured VOCs released by eosinophils and neutrophils 
in vitro, either activated or non-activated and cultured 
in closed flasks and then searched for VOC profiles that 
could discriminate between eosinophilic and neutro-
philic inflammation. The integrative analysis of the 
total amount of volatiles released by eosinophils and 
neutrophils in vitro enables identification of com-
pounds that should be further tested in vivo to discrimi-
nate between inflammatory phenotypes in asthmatics 
and have therapeutic implications.
Methods
In vitro experiments
The approach used comprises freshly isolating 
eosinophils and neutrophils from 30 ml of blood of 
healthy non-smoking volunteers. Non atopic untreated 
blood donors having no respiratory symptoms were 
recruited from the University Hospital of Liege by 
advertisement. Eosinophils and neutrophils were 
isolated by gradient centrifugation, using lymphoprep 
(Axis-Shields, Oslo, Norway). Lymphocytes were 
removed and the remaining erythrocytes were lysed 
using cold (4 °C) lysis buffer (155 mM NH4Cl, 10 mM 
KHCO3 and 10 mM EDTA, pH 7.4). Polymorphonuclear 
leukocytes (PMNs) were then washed and resuspended 
in Hanks balanced salt solution (HBSS; Life technologies, 
Invitrogen, Breda, The Netherlands). Eosinophils were 
separated from neutrophils by immunomagnetic cell 
separation (MACS; Miltenyi Biotec; Bergisch Gladbach, 
Germany) using anti-CD16. Three million cells were 
incubated in an RPMI culture medium supplemented 
with 2% fetal calf serum (FCS) and cultivated under 
standard conditions in 75 cm2 closed culture flasks at 
37 °C with a 5% CO2 atmosphere. Activation of cells 
was realised with phorbol 12-myristate 13-acetate 
(100 ng ml−1, PMA, Sigma). The viability of the cells 
evaluated using trypan blue exclusion at the end of 
the incubation period (90 min) was 95%  ±  4%. VOCs 
from the headspace were collected at time 0′, 30′ and 60′ 
by introduction of ultra-pure nitrogen (99.999% N2) 
in closed flasks at a flow rate of 200 ml min−1 during 
10 min using a recently developed system [18]. To trap 
VOCs, the headspace was pushed out onto a stainless 
steel two-bed sorption tube, filled with carbograph 
1TD/Carbopack X (Markes International Limited, 
Llantrisant, UK).
VOC analysis by GC-TOF-MS
The analytical procedure to measure VOCs by gas 
chromatography—time-of-flight—mass spectrometry 
(GC-TOF-MS) was described in detail earlier [19]. 
Analysis of the samples started with the release of the 
VOC trapped on the sorption tubes using thermal 
desorption by heating the tubes to 270 °C. The gaseous 
mixture of released compounds was then divided; 90% 
of the sample was recollected on a second identical 
sample tube and stored for an optional second analysis. 
10% of the sample was loaded onto a cold (5 °C) 
sorption trap, from which it was injected onto the 
gas chromatography capillary column (RTX-5 ms, 
30 m  ×  0.25 mm 5% diphenyl, 95% dimethylsiloxane 
capillary, film thickness 1 μm). VOC are separated by 
GC (Thermo Fisher Scientific., Austin, Texas, USA) 
and subsequently detected by a time-of-flight mass 
spectrometer (TOF-MS) (Thermo Electron Tempus 
Plus time-of-flight mass spectrometer, ThermoFisher 
Scientific, Austin, Texas, USA). The temperature of 
the gas chromatograph was programmed as follows: 
40 °C during 5 min, then raised with 10 °C/min until 
the final temperature of 270 °C, this temperature was 
maintained for 5 min. The mass spectrometer was 
set at a scan range of 35–350 amu and scan rate of 
5 times/s. The complete analytical procedure, including 
sampling, storage and instrumental analysis, was tested 
for reproducibility [15].
Data-acquisition and mining
Analysis of the data output files from the GC-TOF-
MS was performed in successive steps as previously 
described in detail [20, 21]. In summary, the first step 
was to perform peak detection and baseline corrections 
on all output files. Parts of the chromatograms that 
occurred at a retention index  <0.15 and>2.8 were 
removed, because of unreliable data from these parts. 
Retention times were normalized by calculating 
retention indices, relative to toluene and lining up 
easily recognizable component peaks, to correct for 
chromatographic drifting. The remaining data were 
carefully transformed to excel files. Compounds 
detected in less than 8% of the samples were discarded 
[21]. All components represent chromatographic peaks 
and the components received the same number as the 
corresponding peak.
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Component selection
To determine which compounds in the database 
were of interest regarding the classification of 
eosinophilic versus neutrophilic inflammation, we 
applied a stepwise discriminant analysis using SPSS 
(SPSS 19 for Windows, SPSS Inc. Chicago, IL, USA). 
The discriminant analyses were performed using a 
20-fold cross-over approach. In this method, all but 
5% of the chromatograms are used to construct the 
discriminant function, which is subsequently used to 
predict to which group the ones left out belong. This is 
repeated 20 times, until all samples have been classified 
once. The discriminant functions obtained in this 
way are based on many components and are optimal 
in terms of differentiation between subgroups, but 
are not necessary the best predictors for unknown 
samples, because of potential overfitting. Therefore, 
the number of VOCs is gradually diminished, one 
by one, until a low number of components remains 
with sufficient discriminating power. The reduction 
in components is accomplished by starting with 
the original large set of components from the first 
discriminant analysis and then repeating the analysis 
with the least informative component of the results 
left out.
The chemical identification of the VOCs was done 
by means of spectrum recognition using the The 
National Institute of Standards and Technology (NIST) 
library in combination with spectrum interpretation by 
an experienced mass-spectrometrist and identification 
based on retention times of compounds.
To estimate VOC abundance, chromatograms were 
normalized to total intensity of all peaks, so for every 
peak there is a relative abundance. Comparisons of 
VOC abundance between subgroups were performed 
with a Kruskal–Wallis test. The results were considered 
to be significant at the 5% critical level (p  <  0.05).
This study was conducted with the approval of the 
ethics committee of CHU Liege (2005/181).
Results
Eosinophils and neutrophils were isolated from 26 
healthy non-smoking volunteers. The average number 
of eosinophils and neutrophils upon isolation was 
3.5  ×  106 and 19.4  ×  106, respectively. For both groups, 
16 samples of 3 million cells were activated with PMA 
while 10 samples were not activated.
The resulting analysis of the headspace air demon-
strated that the collected air was rich in a wide variety 
of VOC. For all samples, a total of 2116 compounds 
were found. Compounds detected in less than 8% of 
the samples were discarded resulting in a dataset of 
1123 compounds.
For the discriminant analysis, seven groups were 
defined, as shown in table 1. As we anticipate that VOCs 
may be released from the sampling system and from 
medium and PMA, we used three additional con-
trol groups to limit the risk that discriminant VOCs 
 originate from a non-cellular source. Results of the dis-
criminant analyses are shown in table 2.
We looked at VOCs released after 30, 60 and 90 min of 
incubation. No significant differences between the results 
per time point were detected. We used samples collected 
after 60 min for further analysis. The discriminant analy-
sis for unactivated eosinophils versus unactivated neu-
trophils resulted in a discriminant function comprising 
8 components that classified all samples correctly (100% 
sensitivity and 100% specificity). We gradually dimin-
ished the number of components to build the model, and 
registered the sensitivity and specificity of the analyses 
as a function of the number of components involved. In 
this way, using three components (component 858, 854 
and 843), a 100% correct classification was still obtained. 
With two components (peak 843 and 854) a 100% cor-
rect classification was still achieved whereas one comp-
onent (peak 843) gave 85% correct classification. Within 
this data set, validation was performed using 20-fold 
cross validation with 100% of correctly classified data in 
cross-validated set using 3 components, 100% using two 
components and 85% using one component. Both peak 
843 and 854 displayed higher relative abundance in the 
unactivated neutrophilic when compared to unactivated 
eosinophilic culture (p  <  0.01) and were not detected in 
the flasks not containing inflammatory cells (group 5, 6 
and 7). Looking at the NIST library, we identified peak 
843 as benzylalcohol and peak 854 as 3-methylfuran. 
VOC 858 was found in higher abundance in the unac-
tivated eosinophilic culture as compared to unactivated 
neutrophils and was absent in flasks containing medium 
without cells.
The same approach was used to discriminate 
between activated cell types. Five VOCs distinguish 
between activated eosinophils versus activated neu-
trophils with 96% correct classification in original and 
cross-validated set. With three components (VOC 528, 
486 and 156), we kept 83.3% correctly classified data in 
original dataset and 79.2% in cross-validated set. Chem-
ical identification of peak 528 and 486 gave 1-H-inde-
nol and 2-butoxyethanol. Peak 156 could not be identi-
fied. 1-H-indenol and 2-butoxyethanol were found in 
higher amounts in the neutrophilic culture (p  =  0.0029 
(figure 1) and p  =  0.012 respectively). Moreover, 
the relative abundance of those VOCs was higher in 
activated neutrophils as compared to unactivated 
neutrophils and both VOCs were not detected in the 
Table 1. Description of the 7 groups.
Number 
of flasks VOC source
Group 1 10 Unactivated eosinophils
Group 2 16 Activated eosinophils
Group 3 16 Activated neutrophils
Group 4 10 Unactivated neutrophils
Group 5 15 Medium
Group 6 15 Medium  +  PMA
Group 7 15 Empty flask
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absence of inflammatory cells in the flask. Higher levels 
of VOC 156 were found in eosinophilic cultures, with 
the highest amount of this VOC in unactivated eosin-
ophils (p  =  0.0055). VOC 156 was not present in the 
headspace of flasks not containing inflammatory cells.
We also looked at VOCs released by activated versus 
unactivated eosinophils and activated versus unacti-
vated neutrophils. Peak 254 was able to discriminate 
between activated and unactivated eosinophils and 
was found in higher concentration in the activated state 
(p  <0.0001). This VOC was also found in lower amount 
in the neutrophilic cultures. The chemical identifica-
tion of this compound was para-dichloro-benzene. 
As VOC 634 was also detected in empty flask, this com-
pound was considered not linked to inflammatory cells 
metabolism. VOC 156 was found in higher amounts in 
the unactivated cell cultures (p  =  0.0001 respectively).
Three peaks (peak 842, 839 and 784) were able to 
discriminate between activated versus unactivated neu-
trophils with 100% accuracy. VOC 842, VOC 839 and 
VOC 784 were detected in higher amounts in unacti-
vated neutrophils as compared to activated neutrophils 
(p  <  0.0001). These VOCs were also found in lower 
concentrations in the headspace of unactivated eosino-
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UE versus UN Benzylalcohol 85% 85% 83.3% 85.7%
3-methylfuran 100% 100% 100% 100%
VOC 858 100% 100% 100% 100%
AE versus AN 1-H-indenol 66.7% 66.7% 61.1% 70%
2-butoxyethanol 75% 75% 77.8% 73.3%
VOC 156 83.3% 79.2% 72.2% 83.3%
AE versus UE Para-dichloro-benzene 84% 84% 76.7% 100%
VOC 156 97.7% 97.7% 100% 92.9%
AN versus UN VOC 842 100% 100% 100% 100%
Benzylalcohol 100% 100% 100% 100%
6,10-dimethyl-5,9- dodecadien-2-one 100% 100% 100% 100%
Figure 1. Example of error bars for 1-H-indenol showing the higher concentration of this VOC in the activated neutrophilic culture 
(3) as compared to activated eosinophils (2), unactivated eosinophils (1), unactivated neutrophils (4), medium (5), medium and 
PMA (6), empty flask (7). Results are expressed as mean  +/−  SEM. Flasks from group 1, 2, 3 and 4 contained approximately 3 
millions of cells.
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phils but not detected in the absence of inflammatory 
cells. The chemical identification of these compounds 
was benzylalcohol (peak 839) and 6,10-dimethyl-5,9 
dodecadien-2-one (peak 784). We were not able to 
identify the nature of peak 842.
Percentages are presented for the compounds clas-
sified according to their importance. The percentages 
are cumulative so for the most important compound, 
% are presenting for the use of the sole compound 1 
(first listed). For the second compound of the list, % 
are calculated for the use of both first and second com-
pound. For third compound, the three compounds are 
used together for the prediction. Results are presented 
with sensitivity and specificity. Unactivated eosino-
phils (UEs), unactivated neutrophils (UNs), activated 
eosinophils (AEs) and unactivated neutrophils (ANs).
Discussion
VOCs are carbon-based compounds that are volatile at 
ambient temperature and may result from endogenous 
biochemical pathways including inflammatory 
processes [22]. We were able to identify in vitro VOCs 
discriminating between eosinophil and neutrophil 
cultures, whatever the activation status. When taking 
into account three VOCs or even less to discriminate 
between both cellular types, we observed correct 
classification in the original set and upon cross-
validation with a high accuracy.
A combination of two VOCs was able to discrimi-
nate between unactivated eosinophils and neutrophils 
cell cultures. These VOCs were identified as benzylalco-
hol and 3-methylfuran and seem to reflect neutrophilic 
inflammation. Benzylalcohol was previously identi-
fied in vivo by Ibrahim et al [23] in a model predict-
ing asthma and in this study, a higher concentration 
of this compound in the breath of asthmatic patients 
was found so this could be a good marker in asthmat-
ics exhaled breath to discriminate between eosinophilic 
versus neutrophilic asthma phenotype. Rudnicka 
previously found significantly different concentrations 
of 3-methylfuran between healthy controls and patients 
with lung cancer [24]. It is interesting as it was previ-
ously shown in the literature that patients with lung 
cancer exhibit higher levels of neutrophils in induced 
sputum [25]. Moreover, 3-methylfuran was also found 
in higher amounts in the breath of smoking and pas-
sive smoking healthy volunteers [26], and smokers have 
been shown to exhibit higher bronchial neutrophilic 
inflammation. VOC 858 remained unidentified and 
seems to be a marker of eosinophils.
Concerning the activated cell cultures, 1-H-inde-
nol and 2-butoxyethanol were found to be able to 
discriminate between eosinophils and neutrophils. 
1-H-indenol and 2-butoxyethanol were found in 
higher amounts in the neutrophilic culture and the 
abundance of those VOC was higher in activated 
neutrophils as compared to unactivated neutrophils. 
This suggests that both VOCs could be products of the 
neutrophilic metabolism while VOC156 seems to be a 
marker of eosinophils.
We also looked at activated versus unactivated 
eosinophils to try to identify markers released by acti-
vated eosinophils. A potential source for generation of 
microbicidal superoxide is the NADPH oxidase found 
in neutrophils and eosinophils. Most of superoxide 
generated in vivo undergoes a nonenzymatic or SOD 
catalysed reaction resulting in its dismutation into 
hydrogen peroxide (H2O2). Once formed, the oxidiz-
ing potential of H2O2 may be amplified by eosinophil 
peroxidase (EPO) and myeloperoxidase (MPO) that cat-
alyze conversion of reduced oxygen species (superoxide) 
into the more reactive OH.. When activated, eosinophils 
release eosinophil peroxidase which is responsible for 
brominated or chlorinated agents production. Indeed, 
para-dichloro-benzene was found in higher concen-
trations in activated than in unactivated eosinophil 
culture and thus showed to be a promising biomarker 
able to discriminate the activated from the unactivated 
state. The two VOCs able to discriminate between acti-
vated and unactivated neutrophils with 100% accuracy 
were identified as Benzylalcohol and 6,10-dimethyl-5,9 
dodecadien-2-one. It seems that both VOC are products 
of neutrophilic metabolism as they were not detected in 
unactivated neutrophilic culture.
The identification of VOCs related to eosinophilic 
and neutrophilic inflammation give the possibil-
ity to develop a device such as eNose that could non- 
invasively and potentially quickly identify bronchial 
inflammation. This is important as eosinophilic inflam-
mation is more reflect of allergens exposure while neu-
trophils may reflect underlying infectious process. 
Patients presenting with respiratory symptoms in 
whom the clinician identify exhaled markers of eosino-
philic inflammation could benefit from corticosteroids 
while those with markers of neutrophilic inflammation 
would be better improved with antibiotics.
In conclusion, analysis of VOCs seems very prom-
ising in identifying eosinophilic and neutrophilic 
inflammation but needs further development and 
in vivo confirmation.
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